David Bailey Buys 4,918 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,918 shares of the stock in a transaction dated Tuesday, August 18th. The shares were acquired at an average price of $5.12 per share, for a total transaction of $25,180.16. Following the completion of the purchase, the chief executive officer directly owned 3,180,394 shares in the company, valued at approximately $16,283,617.28. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

KindlyMD Stock Up 12.1%

NAKA opened at $7.06 on Friday. The stock has a market cap of $126.34 million, a price-to-earnings ratio of -0.20 and a beta of 15.95. The company’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $7.24. KindlyMD, Inc. has a twelve month low of $3.33 and a twelve month high of $422.40.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. The firm had revenue of $35.87 million for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. As a group, sell-side analysts anticipate that KindlyMD, Inc. will post -11.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen lifted their price target on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.33.

Key Headlines Impacting KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Institutional Trading of KindlyMD

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in KindlyMD by 76.2% in the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after purchasing an additional 8,386 shares during the period. Osaic Holdings Inc. bought a new stake in shares of KindlyMD during the second quarter valued at approximately $215,000. Tower Research Capital LLC TRC increased its holdings in shares of KindlyMD by 1,638.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after purchasing an additional 31,245 shares in the last quarter. Victory Capital Management Inc. purchased a new position in KindlyMD in the 3rd quarter worth about $1,007,000. Finally, Vident Advisory LLC purchased a new position in shares of KindlyMD during the third quarter valued at approximately $2,092,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.